ACHIEVE LIFE SCIENCES, INC.

ACHVSEC EDGAR

In Vitro & In Vivo Diagnostic Substances(DE)CIK: 949858

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue from Contract with Customer, Excluding Assessed Tax	—	—	—	—	—
Research and Development Expense	$30.1M	$24.0M	$6.9M	$9.7M	$5.9M
Operating Expenses	—	—	—	—	—
Interest Expense	—	$1.8M	$1.8M	—	—
Nonoperating Income (Expense)	-$1.6M	-$58.0K	$20.0K	$133.0K	$126.0K
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$42.4M	-$33.2M	-$14.7M	-$16.4M	—
Income Tax Expense (Benefit)	—	—	—	—	—

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$19.4M	$30.0M	$47.5M	$40.3M	$21.1M
Assets, Current	$17.0M	$27.3M	$44.6M	$37.0M	$17.3M
Cash and Cash Equivalents, at Carrying Value	$15.5M	$24.8M	$43.0M	$35.9M	$16.7M
Accounts Receivable, after Allowance for Credit Loss, Current	—	—	—	—	—
Liabilities	$20.8M	$21.7M	$19.5M	$3.0M	$3.0M
Liabilities, Current	$20.8M	$21.6M	$4.5M	$2.9M	$2.9M
Accounts Payable, Current	$618.0K	$1.7M	$841.0K	$332.0K

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$37.6M	-$29.4M	-$13.5M	-$15.2M	-$10.6M
Net Cash Provided by (Used in) Investing Activities	-$21.0K	-$21.0K	-$17.0K	$5.0M	-$5.1M
Net Cash Provided by (Used in) Financing Activities	$19.3M	$36.6M	$32.7M	$17.3M	$19.8M
Payments to Acquire Property, Plant, and Equipment	$21.0K	$21.0K	$17.0K	$53.0K	$46.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)